Safety, immunogenicity, and excretion pattern of single-dose live oral cholera vaccine CVD 103-HgR in Peruvian adults of high and low socioeconomic levels
- PMID: 8359923
- PMCID: PMC281106
- DOI: 10.1128/iai.61.9.3994-3997.1993
Safety, immunogenicity, and excretion pattern of single-dose live oral cholera vaccine CVD 103-HgR in Peruvian adults of high and low socioeconomic levels
Abstract
Groups of 122 Peruvian adults of low socioeconomic level (SEL) and 125 of high SEL received a randomly allocated 5 x 10(9)- or 5 x 10(8)-CFU dose of CVD 103-HgR live oral cholera vaccine or a placebo. The vaccine was well tolerated. Vibriocidal seroconversions occurred in 78% of high-SEL and 72% of low-SEL subjects who ingested the high dose and in 78 and 49%, respectively, of those who received the low dose.
Similar articles
-
Palatability, reactogenicity and immunogenicity of engineered live oral cholera vaccine CVD 103-HgR in Chilean infants and toddlers.Pediatr Infect Dis J. 1999 Jul;18(7):624-30. doi: 10.1097/00006454-199907000-00011. Pediatr Infect Dis J. 1999. PMID: 10440439 Clinical Trial.
-
Safety and immunogenicity of single-dose live oral cholera vaccine CVD 103-HgR in 5-9-year-old Indonesian children.Lancet. 1992 Sep 19;340(8821):689-94. doi: 10.1016/0140-6736(92)92231-4. Lancet. 1992. PMID: 1355798 Clinical Trial.
-
Evaluation of a bivalent (CVD 103-HgR/CVD 111) live oral cholera vaccine in adult volunteers from the United States and Peru.Infect Immun. 1997 Sep;65(9):3852-6. doi: 10.1128/iai.65.9.3852-3856.1997. Infect Immun. 1997. PMID: 9284163 Free PMC article. Clinical Trial.
-
PaxVax CVD 103-HgR single-dose live oral cholera vaccine.Expert Rev Vaccines. 2017 Mar;16(3):197-213. doi: 10.1080/14760584.2017.1291348. Expert Rev Vaccines. 2017. PMID: 28165831 Review.
-
Biosafety aspects of the recombinant live oral Vibrio cholerae vaccine strain CVD 103-HgR.Vaccine. 2004 Jun 23;22(19):2457-69. doi: 10.1016/j.vaccine.2003.12.033. Vaccine. 2004. PMID: 15193410 Review.
Cited by
-
Immunogenicity and efficacy of oral vaccines in developing countries: lessons from a live cholera vaccine.BMC Biol. 2010 Oct 4;8:129. doi: 10.1186/1741-7007-8-129. BMC Biol. 2010. PMID: 20920375 Free PMC article. Review.
-
Safety and immunogenicity assessment of an oral cholera vaccine through phase I clinical trial in Korea.J Korean Med Sci. 2014 Apr;29(4):494-501. doi: 10.3346/jkms.2014.29.4.494. Epub 2014 Apr 1. J Korean Med Sci. 2014. PMID: 24753695 Free PMC article. Clinical Trial.
-
A single dose of live oral cholera vaccine CVD 103-HgR is safe and immunogenic in HIV-infected and HIV-noninfected adults in Mali.Bull World Health Organ. 1998;76(1):63-71. Bull World Health Organ. 1998. PMID: 9615498 Free PMC article. Clinical Trial.
-
Transient Intestinal Colonization by a Live-Attenuated Oral Cholera Vaccine Induces Protective Immune Responses in Streptomycin-Treated Mice.J Bacteriol. 2020 Nov 19;202(24):e00232-20. doi: 10.1128/JB.00232-20. Print 2020 Nov 19. J Bacteriol. 2020. PMID: 32540930 Free PMC article.
-
Maximizing protection from use of oral cholera vaccines in developing country settings: an immunological review of oral cholera vaccines.Hum Vaccin Immunother. 2014;10(6):1457-65. doi: 10.4161/hv.29199. Epub 2014 May 26. Hum Vaccin Immunother. 2014. PMID: 24861554 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources